Is Visceral Adiposity the “Enemy Within”?
2001; Lippincott Williams & Wilkins; Volume: 21; Issue: 6 Linguagem: Inglês
10.1161/01.atv.21.6.881
ISSN1524-4636
Autores Tópico(s)Atherosclerosis and Cardiovascular Diseases
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 21, No. 6Is Visceral Adiposity the "Enemy Within"? Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBIs Visceral Adiposity the "Enemy Within"? Russell P. Tracy Russell P. TracyRussell P. Tracy From the University of Vermont College of Medicine, Colchester. Originally published1 Jun 2001https://doi.org/10.1161/01.ATV.21.6.881Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:881–883Recently, data from diverse areas of investigation have come together to implicate chronic low-level inflammation as an important pathogenetic factor in atherosclerotic cardiovascular disease (CVD). As recently summarized by Ross,1 studies in cell biology, animal models, clinical research, and epidemiology have been remarkably consistent in validating the early work of Virchow2 and others, suggesting that atherosclerotic lesions are essentially an inflammatory response. In clinical research and epidemiology, 2 inflammation blood markers in particular, fibrinogen and C-reactive protein (CRP), have been used. Many studies have confirmed that these markers predict future cardiovascular events independently of more traditional cardiovascular risk factors, such as plasma lipid levels.345 Because of this, several investigators have suggested that CRP might prove useful in clinical practice,67 whereas others have favored fibrinogen.89 Although there are important details to work out before either of these markers enters the clinical domain, this interest provides a clear and compelling imperative for understanding how inflammation integrates into both normal physiology and atherothrombotic pathophysiology.Focusing on CRP, population-based research efforts have revealed that in general, women have slightly higher values than men, blacks have higher values than whites, and those with clinical CVD have higher values than those without10111213 (M. Cushman, et al, manuscript in preparation). In those without clinical CVD, metabolic variables consistently correlated with CRP include body mass index (BMI), glucose tolerance status/diabetes status, and level of coagulation activation. In addition, depending on the population being studied, other correlates of CRP may include smoking status, plasma lipids (especially HDL cholesterol), hypertension, evidence of chronic infection, and measures of subclinical atherosclerotic disease, such as ankle-brachial blood pressure index (ABI).Whether or not some variables have been identified as significant correlates appears to depend, at least in part, on the presence and/or extent of other variables in the analysis. For example, in the nonsmokers of the Cardiovascular Health Study, diabetes status was a strong correlate of CRP but ABI was not; in the smokers, in whom pack-years of smoking was strongly correlated with CRP, diabetes status was no longer significant but ABI was.11 In another example, all measures related to carbohydrate metabolism were correlated with CRP in the Insulin Resistance and Atherosclerosis Study (IRAS), which had participants within a broad range of insulin sensitivity and diabetes status.12 Neither smoking nor measures of subclinical atherosclerosis such as carotid artery wall thickness, however, were correlated with CRP in this group. This variability in correlation suggests that unless significant acute inflammation is present, ambient levels of CRP and underlying regulators such as interleukin-6 are tightly regulated and rarely exceed upper limits. This is logical, because the underlying inflammation system appears to be pervasive and connected to a wide variety of homeostatic and defensive processes.14Despite this variability in the association of some variables with CRP, a measure of obesity (usually BMI) has been relatively strongly correlated with CRP in virtually all analyses done to date. Two articles in the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology address this now well-established association. Both articles extend our knowledge in this area and provide important new insights into the regulation of inflammation status. The report by Lemieux et al15 focuses on a detailed analysis of body composition in healthy middle-aged men with atherogenic dyslipidemia and a wide range of BMI (21 to 41 kg/m2). They used hydrostatic weighing and computed tomography to make state-of-the-art assessments of body fat, extending the work of Yudkin and others,101113 finding strong positive correlations of CRP with body fat mass, waist girth, and visceral fat. Confirming the analysis done in IRAS,12 they also observed a strong relationship to insulin levels assessed over time during a 75-g oral glucose load. In this group of men, they failed to observe any significant association of CRP with plasma lipid levels, concluding that in men with atherogenic dyslipidemia associated with the metabolic syndrome, it is abdominal obesity that is the "critical correlate" of CRP.These findings have several important implications. First, the data fit well with a growing body of evidence implicating adipose tissue in general, and visceral adiposity in particular, as key regulators of inflammation, coagulation, and fibrinolysis.16 Adipose tissue secretes proinflammatory cytokines1317 and fibrinolytic regulators such as plasminogen activator inhibitor-1.18 Along with many possible roles in atherogenesis and atherosclerotic progression, inflammatory mediators can activate coagulation by stimulating monocytes to express tissue factor19 (as can CRP itself20 ) and by causing disregulation in natural anticoagulation.21 They can affect fibrinolytic balance22 and have been implicated as a possible pathogenetic agent in the development of insulin resistance,23 the latter being consistent with the ability of inflammation markers to predict the future occurrence of diabetes.24 As a major source of proinflammatory cytokines, adipose tissue becomes linked at the molecular level to the disregulation of a variety of underlying systems, all of which are causally implicated in the development of atherosclerotic, thrombotic, and metabolic outcomes.Second, although subcutaneous fat clearly plays an important role,17 the identification of visceral adiposity as a key correlate of CRP in these men is consistent not only with the emerging role of abdominal fat in the metabolic syndrome25 but also with the concept of "nonoverweight obesity" as proffered by Dvorak and colleagues.26 They suggested that the role of visceral fat may be more complex than suspected, because even people who are not obviously overweight may still have disproportionately too much visceral fat, with the result of a predisposition toward insulin resistance and atherosclerotic disease, possibly through inappropriate cytokine secretion. If true, this concept begs the question of whether the key variable might not be disproportionate visceral adiposity rather than what has traditionally been considered obesity as characterized by weight, waist girth, or BMI.Finally, adiposity may offer a target for modification of inflammation status. The evidence that inflammation is a pathogenetic factor in atherosclerosis is strong, and Lemieux et al conclude their article by suggesting that inflammation may be a modifiable risk factor, citing recent clinical trial data involving aspirin, statins, and fibrates.27282930 They also suggest that because of the powerful association with obesity, weight loss may be another method for downregulating an individual's inflammatory status. This point is directly addressed by the second article, the report by Heilbronn et al.31 They studied a group of healthy obese women, characterized by an average BMI of 34 kg/m2, with a range of 28 to 44 kg/m2. These subjects were placed on a very-low-fat diet for 12 weeks and achieved an average weight loss of 8 kg. CRP decreased by 26%, and the authors observed a strong correlation between weight loss and change in CRP (r=0.3, P=0.005).This observation has important health implications. Although there are no direct data involving CRP or the proinflammatory cytokines it reflects in human atherosclerotic disease, research using the murine model of atherosclerosis has shown such results,32 and the indirect data in humans are consistent and becoming compelling. From a mechanistic standpoint, several possible pathways for interleukin-6, tumor necrosis factor-α, and CRP have been identified, eg, the activation of monocytes and endothelial cells.2033 Clinically, in the Physicians Health Study, the ability of aspirin to protect against a first CVD event was strongly linked to higher CRP levels,29 and statins appear to work most effectively in people with higher CRP values.2728 Although the ability of aspirin to lower CRP is uncertain, statins clearly do so.3435 Therefore, it is reasonable to hypothesize that other methods that have a CRP-lowering effect, such as weight loss, may prove more effective in those with higher CRP values (ie, higher ambient inflammatory status). Because CRP levels are also associated cross-sectionally with activity status,36 this finding suggests a similar hypothesis related to exercise.We and others have recently observed that unlike statins, hormone replacement therapy in the form of estrogen, but not estrogen-like synthetic drugs, raises CRP levels dramatically.37383940 On the basis of observational studies, estrogen has traditionally been considered an influence for the better with regard to CVD risk. The recent results from the HERS trial, identifying a significant CVD risk for some women in the first year or so after the start of estrogen therapy,41 however, raise the question of whether drugs that raise CRP may carry an unwanted risk based on their effects on inflammation. In addition, one might ask whether those with greater visceral fat deposits might be at even greater risk because of a possibly increased potential for proinflammatory response. These hypotheses will be tested directly in several ongoing hormone replacement clinical trials.In summary, an emerging body of evidence suggests that abdominal fat is a key regulatory site for the general processes of inflammation, coagulation, and fibrinolysis. These processes may be altered by behaviors, such as diet and exercise, that affect fat deposits, as well as by medications, in both positive and negative ways. These effects have long-term implications for chronic outcomes such as CVD and type 2 diabetes, which we are only beginning to understand.FootnotesCorrespondence to Dr Russell P. Tracy, University of Vermont, Departments of Pathology and Biochemistry, 55A South Park Dr, Colchester, VT 05446. References 1 Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med.1999; 340:115–126.CrossrefMedlineGoogle Scholar2 Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. Berlin, Germany; 1858.Google Scholar3 Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA.1998; 279:1477–1482.CrossrefMedlineGoogle Scholar4 Ridker PM. Novel risk factors and markers for coronary disease. Adv Intern Med.2000; 45:391–418.MedlineGoogle Scholar5 Tracy RP. Inflammation markers and coronary heart disease. Curr Opin Lipidol.1999; 10:435–441.CrossrefMedlineGoogle Scholar6 Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem.2001; 47:28–30.CrossrefMedlineGoogle Scholar7 Tracy RP. Inflammation in cardiovascular disease: cart, horse, or both? Circulation.1998; 97:2000–2002.CrossrefMedlineGoogle Scholar8 Ernst E, Koenig W. Fibrinogen and cardiovascular risk. Vasc Med.1997; 2:115–125.CrossrefMedlineGoogle Scholar9 Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J. 1998;19(suppl H):H11–H17.Google Scholar10 Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study [see comments]. BMJ.1996; 312:1061–1065.CrossrefMedlineGoogle Scholar11 Tracy R, Macy E, Bovill E, Cushman M, Psaty B, Cornell E, Kuller L. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol.1997; 17:2167–2176.CrossrefMedlineGoogle Scholar12 Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation.2000; 102:42–47.CrossrefMedlineGoogle Scholar13 Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol.1999; 19:972–978.CrossrefMedlineGoogle Scholar14 Aggawal B, Puri R, eds. Human Cytokines: Their Role in Disease and Therapy. Cambridge, Mass: Blackwell Science; 1995.Google Scholar15 Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, Bergeron J, Després J-P. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol.2001; 21:961–967.CrossrefMedlineGoogle Scholar16 Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent? Diabetes Care. 1999;22(suppl 3):C25–C30.Google Scholar17 Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab.1997; 82:4196–4200.MedlineGoogle Scholar18 Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity: studies of PAI-1. Arterioscler Thromb Vasc Biol.1998; 18:1–6.CrossrefMedlineGoogle Scholar19 Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol.1989; 9:2752–2755.CrossrefMedlineGoogle Scholar20 Cermak J, Key N, Bach R, Balla J, Jacob H, Vercellotti G. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood.1993; 82:513–520.CrossrefMedlineGoogle Scholar21 Esmon C, Taylor F, Snow T. Inflammation and coagulation: linked processes potentially regulated through a common pathway mediated by protein C. Thromb Haemost.1991; 66:160–165.CrossrefMedlineGoogle Scholar22 Kluft C, Verheijen J, Jie A, Rijken D, Preston F, Sue-Ling H, Jespersen J, Aasen A. The post-operative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest.1985; 45:605–610.CrossrefMedlineGoogle Scholar23 Cheung AT, Ree D, Kolls JK, Fuselier J, Coy DH, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology.1998; 139:4928–4935.CrossrefMedlineGoogle Scholar24 Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet.1999; 353:1649–1652.CrossrefMedlineGoogle Scholar25 Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes.2000; 49:883–888.CrossrefMedlineGoogle Scholar26 Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normal-weight young women. Diabetes.1999; 48:2210–2214.CrossrefMedlineGoogle Scholar27 Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation.1998; 98:839–844.CrossrefMedlineGoogle Scholar28 Horne BD, Muhlestein JB, Carlquist JF, Bair TL, Madsen TE, Hart NI, Anderson JL. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol.2000; 36:1774–1780.CrossrefMedlineGoogle Scholar29 Ridker P, Cushman M, Stampfer M, Tracy R, Hennekens C. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med.1997; 336:973–979.CrossrefMedlineGoogle Scholar30 Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature.1998; 393:790–793.CrossrefMedlineGoogle Scholar31 Heilbronn LK, Noakes M, Clifton MP. Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. Atheroscler Thromb Vasc Biol.2001; 21:968–970.CrossrefMedlineGoogle Scholar32 Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol.1999; 19:2364–2367.CrossrefMedlineGoogle Scholar33 Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation.2000; 102:2165–2168.CrossrefMedlineGoogle Scholar34 Strandberg TE, Vanhanen H, Tikkanen MJ. Effect of statins on C-reactive protein in patients with coronary artery disease [letter] [see comments]. Lancet.1999; 353:118–119.CrossrefMedlineGoogle Scholar35 Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation.2001; 103:1191–1193.CrossrefMedlineGoogle Scholar36 Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP. Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol.2001; 153:242–250.CrossrefMedlineGoogle Scholar37 Cushman M, Meilahn EN, Psaty BM, Kuller LH, Dobs AS, Tracy RP. Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol.1999; 19:893–899.CrossrefMedlineGoogle Scholar38 Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation.1999; 100:717–722.CrossrefMedlineGoogle Scholar39 Ridker PM, Hennekens CH, Rifai N, Buring JE, Manson JE. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation.1999; 100:713–716.CrossrefMedlineGoogle Scholar40 Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab.2000; 85:214–218.MedlineGoogle Scholar41 Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group [see comments]. JAMA.1998; 280:605–613.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Dalbem C, Dalbem C, Nunes J, Macedo T, Alves B and dos Santos L (2022) DXA and Bioelectrical Impedance: Evaluative Comparison in Obese Patients in City of Cáceres XXVII Brazilian Congress on Biomedical Engineering, 10.1007/978-3-030-70601-2_343, (2337-2340), . Kulshrestha H, Gupta V, Mishra S, Mahdi A, Awasthi S and Kumar S (2018) Interleukin-10 as a novel biomarker of metabolic risk factors, Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 10.1016/j.dsx.2018.03.019, 12:4, (543-547), Online publication date: 1-Jul-2018. Liu Y, Cromeens B, Wang Y, Fisher K, Johnson J, Chakroff J and Besner G (2018) Comparison of Different In Vivo Incubation Sites to Produce Tissue-Engineered Small Intestine , Tissue Engineering Part A, 10.1089/ten.tea.2017.0313, 24:13-14, (1138-1147), Online publication date: 1-Jul-2018. Fatima S, Jamil Z, Abidi S, Nadeem D, Bashir Z and Ansari A (2017) Interleukin-18 polymorphism as an inflammatory index in metabolic syndrome: A preliminary study, World Journal of Diabetes, 10.4239/wjd.v8.i6.304, 8:6, (304), . Coffey J and O'leary D (2017) Defining the mesentery as an organ and what this means for understanding its roles in digestive disorders, Expert Review of Gastroenterology & Hepatology, 10.1080/17474124.2017.1329010, 11:8, (703-705), Online publication date: 3-Aug-2017. Coffey J and O'Leary D (2016) The mesentery: structure, function, and role in disease, The Lancet Gastroenterology & Hepatology, 10.1016/S2468-1253(16)30026-7, 1:3, (238-247), Online publication date: 1-Nov-2016. Scridon A, Dobreanu D, Chevalier P and Şerban R (2015) Inflammation, a link between obesity and atrial fibrillation, Inflammation Research, 10.1007/s00011-015-0827-8, 64:6, (383-393), Online publication date: 1-Jun-2015. Gross R, Groer M and Thomas S (2014) Relationship of Trait Anger and Anger Expression to C-Reactive Protein in Postmenopausal Women, Health Care for Women International, 10.1080/07399332.2013.862798, 35:5, (580-595), Online publication date: 4-May-2014. Hwang I, Suh S, Seo A, Ahn H and Yim E (2012) Association between Metabolic Components and Subclinical Atherosclerosis in Korean Adults, Korean Journal of Family Medicine, 10.4082/kjfm.2012.33.4.229, 33:4, (229), . Bhuiyan A, Srinivasan S, Chen W, Azevedo M and Berenson G (2011) Influence of low birth weight on C-reactive protein in asymptomatic younger adults: the bogalusa heart study, BMC Research Notes, 10.1186/1756-0500-4-71, 4:1, Online publication date: 1-Dec-2011. Dozio E, Malavazos A, Dogliotti G, Goggi S, Galliera E, Solimene U, Magni P, Costa E, Morricone L and Corsi M (2011) Asymmetric Dimethylarginine: Relationship with Circulating Biomarkers of Inflammation and Cardiovascular Disease Risk in Uncomplicated Obese Women, European Journal of Inflammation, 10.1177/1721727X1100900305, 9:3, (249-255), Online publication date: 1-Sep-2011. Stapleton R, Dixon A, Parsons P, Ware L and Suratt B (2010) The Association Between BMI and Plasma Cytokine Levels in Patients With Acute Lung Injury, Chest, 10.1378/chest.10-0014, 138:3, (568-577), Online publication date: 1-Sep-2010. Muller A, Tort A, Gnoatto J, Moreira J, Vinadé E, Perry M, Souza D, Lara D and Portela L (2010) Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats, Behavioural Pharmacology, 10.1097/FBP.0b013e32833e7f2a, 21:7, (668-675), Online publication date: 1-Oct-2010. Srikanthan P, Seeman T and Karlamangla A (2009) Waist-Hip-Ratio as a Predictor of All-Cause Mortality in High-Functioning Older Adults, Annals of Epidemiology, 10.1016/j.annepidem.2009.05.003, 19:10, (724-731), Online publication date: 1-Oct-2009. Beasley L, Koster A, Newman A, Javaid M, Ferrucci L, Kritchevsky S, Kuller L, Pahor M, Schaap L, Visser M, Rubin S, Goodpaster B and Harris T (2012) Inflammation and Race and Gender Differences in Computerized Tomography-measured Adipose Depots, Obesity, 10.1038/oby.2008.627, 17:5, (1062-1069), Online publication date: 1-May-2009. Castro C, Tracy R, Deckelbaum R, Basch C and Shea S Adiposity is Associated with Endothelial Activation in Healthy 2-3 Year-old Children, Journal of Pediatric Endocrinology and Metabolism, 10.1515/JPEM.2009.22.10.905, 22:10 Simón I, Escoté X, Vilarrasa N, Gómez J, Fernández-Real J, Megía A, Gutiérrez C, Gallart L, Masdevall C and Vendrell J (2012) Adipocyte Fatty Acid-binding Protein as a Determinant of Insulin Sensitivity in Morbid-obese Women, Obesity, 10.1038/oby.2008.665, 17:6, (1124-1128), Online publication date: 1-Jun-2009. Aiello A and Kaplan G (2009) Socioeconomic Position and Inflammatory and Immune Biomarkers of Cardiovascular Disease: Applications to the Panel Study of Income Dynamics, Biodemography and Social Biology, 10.1080/19485560903382304, 55:2, (178-205), Online publication date: 3-Dec-2009. Snitker S, Fujishima Y, Shen H, Ott S, Pi-Sunyer X, Furuhata Y, Sato H and Takahashi M (2008) Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications, The American Journal of Clinical Nutrition, 10.3945/ajcn.2008.26561, 89:1, (45-50), Online publication date: 1-Jan-2009. Catov J, Newman A, Roberts J, Sutton–Tyrrell K, Kelsey S, Harris T, Jackson R, Colbert L, Satterfield S, Ayonayon H and Ness R (2007) Association Between Infant Birth Weight and Maternal Cardiovascular Risk Factors in the Health, Aging, and Body Composition Study, Annals of Epidemiology, 10.1016/j.annepidem.2006.02.007, 17:1, (36-43), Online publication date: 1-Jan-2007. Chapidze G, Dolidze N, Enquobahrie D, Kapanadze S, Latsabidze N and Williams M (2007) Metabolic Syndrome and C-reactive Protein among Cardiology Patients, Archives of Medical Research, 10.1016/j.arcmed.2007.03.011, 38:7, (783-788), Online publication date: 1-Oct-2007. Kling M, Alesci S, Csako G, Costello R, Luckenbaugh D, Bonne O, Duncko R, Drevets W, Manji H, Charney D, Gold P and Neumeister A (2007) Sustained Low-Grade Pro-inflammatory State in Unmedicated, Remitted Women with Major Depressive Disorder as Evidenced by Elevated Serum Levels of the Acute Phase Proteins C-reactive Protein and Serum Amyloid A, Biological Psychiatry, 10.1016/j.biopsych.2006.09.033, 62:4, (309-313), Online publication date: 1-Aug-2007. Vilarrasa N, Vendrell J, Sánchez-Santos R, Broch M, Megia A, Masdevall C, Gomez N, Soler J, Pujol J, Bettónica C, Aranda H and Gómez J (2007) Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-α receptors, C-reactive protein and adiponectin in morbidly obese patients, Clinical Endocrinology, 10.1111/j.1365-2265.2007.02945.x, 67:5, (679-686), Online publication date: 1-Nov-2007. Stamatelopoulos K, Lekakis J, Vamvakou G, Katsichti P, Protogerou A, Revela I, Karatzi K, Alevizaki M, Zakopoulos N and Papamichael C (2007) The relative impact of different measures of adiposity on markers of early atherosclerosis, International Journal of Cardiology, 10.1016/j.ijcard.2006.07.098, 119:2, (139-146), Online publication date: 1-Jul-2007. Patel D, Srinivasan S, Xu J, Li S, Chen W and Berenson G (2006) Distribution and metabolic syndrome correlates of plasma C-reactive protein in biracial (black-white) younger adults: the Bogalusa Heart Study, Metabolism, 10.1016/j.metabol.2005.07.015, 55:6, (699-705), Online publication date: 1-Jun-2006. Jae S, Fernhall B, Heffernan K, Jeong M, Chun E, Sung J, Lee S, Lim Y and Park W (2006) Effects of lifestyle modifications on C-reactive protein: contribution of weight loss and improved aerobic capacity, Metabolism, 10.1016/j.metabol.2006.02.010, 55:6, (825-831), Online publication date: 1-Jun-2006. Bozdemir A, Barutcuoglu B, Dereli D, Kabaroglu C, Habif S and Bayındır O C-Reactive protein and neopterin levels in healthy non-obese adults, Clinical Chemistry and Laboratory Medicine (CCLM), 10.1515/CCLM.2006.055, 44:3 Haupt D, Luber A, Maeda J, Melson A, Schweiger J and Newcomer J (2004) Plasma Leptin and Adiposity During Antipsychotic Treatment of Schizophrenia, Neuropsychopharmacology, 10.1038/sj.npp.1300563, 30:1, (184-191), Online publication date: 1-Jan-2005. Hsieh C, Wang P, Liu R, Tung S, Chien W, Chen J, Chen C, Kuo M and Hu Y (2005) Orlistat for obesity: benefits beyond weight loss, Diabetes Research and Clinical Practice, 10.1016/j.diabres.2004.05.012, 67:1, (78-83), Online publication date: 1-Jan-2005. Hsieh C and Wang P (2014) Effectiveness of weight loss in the elderly with Type 2 diabetes mellitus, Journal of Endocrinological Investigation, 10.1007/BF03345334, 28:2, (973-977), Online publication date: 1-Feb-2005. Roerig J, Mitchell J, de Zwaan M, Crosby R, Gosnell B, Steffen K and Wonderlich S (2005) A Comparison of the Effects of Olanzapine and Risperidone Versus Placebo on Eating Behaviors, Journal of Clinical Psychopharmacology, 10.1097/01.jcp.0000177549.36585.29, 25:5, (413-418), Online publication date: 1-Oct-2005. Carter A (2016) Inflammation, thrombosis and acute coronary syndromes, Diabetes and Vascular Disease Research, 10.3132/dvdr.2005.018, 2:3, (113-121), Online publication date: 1-Oct-2005. Robinson L and Graham T (2004) Metabolic Syndrome, a Cardiovascular Disease Risk Factor: Role of Adipocytokines and Impact of Diet and Physical Activity, Canadian Journal of Applied Physiology, 10.1139/h04-053, 29:6, (808-829), Online publication date: 1-Dec-2004. Marfella R, Esposito K, Siniscalchi M, Cacciapuoti F, Giugliano F, Labriola D, Ciotola M, Di Palo C, Misso L and Giugliano D (2004) Effect of Weight Loss on Cardiac Synchronization and Proinflammatory Cytokines in Premenopausal Obese Women, Diabetes Care, 10.2337/diacare.27.1.47, 27:1, (47-52), Online publication date: 1-Jan-2004. Giugliano G, Nicoletti G, Grella E, Giugliano F, Esposito K, Scuderi N and D'Andrea F (2004) Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women, British Journal of Plastic Surgery, 10.1016/j.bjps.2003.12.010, 57:3, (190-194), Online publication date: 1-Apr-2004. Leinonen E, Hurt-Camejo E, Wiklund O, Hultén L, Hiukka A and Taskinen M (2003) Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes, Atherosclerosis, 10.1016/S0021-9150(02)00371-4, 166:2, (387-394), Online publication date: 1-Feb-2003. Isasi C, Deckelbaum R, Tracy R, Starc T, Berglund L and Shea S (2003) Physical Fitness and C-Reactive Protein Level in Children and Young Adults: The Columbia University BioMarkers Study, Pediatrics, 10.1542/peds.111.2.332, 111:2, (332-338), Online publication date: 1-Feb-2003. Reed D, Dwyer K and Dwyer J (2003) Abdominal obesity and carotid artery wall thickness. The Los Angeles Atherosclerosis Study, International Journal of Obesity, 10.1038/sj.ijo.0802468, 27:12, (1546-1551), Online publication date: 1-Dec-2003. Nicoletti G, Giugliano G, Pontillo A, Cioffi M, D'Andrea F, Giugliano D and Esposito K (2014) Effect of a multidisciplinary program of weight reduction on endothelial functions in obese women, Journal of Endocrinological Investigation, 10.1007/BF03345154, 26:3, (RC5-RC8), Online publication date: 1-Mar-2003. McVeigh G and Cohn J (2003) Endothelial dysfunction and the metabolic syndrome, Current Diabetes Reports, 10.1007/s11892-003-0059-0, 3:1, (87-92), Online publication date: 1-Jan-2003. Werneke U, Taylor D, Sanders T and Wessely S (2003) Behavioural management of antipsychotic-induced weight gain: a review, Acta Psychiatrica Scandinavica, 10.1034/j.1600-0447.2003.00190.x, 108:4, (252-259), Online publication date: 1-Oct-2003. Tracy R (2003) Thrombin, Inflammation, and Cardiovascular Disease, Chest, 10.1378/chest.124.3_suppl.49S, 124:3, (49S-57S), Online publication date: 1-Sep-2003. Shea S, Aymong E, Zybert P, Shamoon H, Tracy R, Deckelbaum R and Basch C (2012) Obesity, Fasting Plasma Insulin, and C-Reactive Protein Levels in Healthy Children, Obesity Research, 10.1038/oby.2003.15, 11:1, (95-103), Online publication date: 1-Jan-2003. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G and Giugliano D (2003) Association of Low Interleukin-10 Levels with the Metabolic Syndrome in Obese Women, The Journal of Clinical Endocrinology & Metabolism, 10.1210/jc.2002-021437, 88:3, (1055-1058), Online publication date: 1-Mar-2003. Werneke U, Taylor D and Sanders T (2002) Options for pharmacological management of obesity in patients treated with atypical antipsychotics, International Clinical Psychopharmacology, 10.1097/00004850-200207000-00001, 17:4, (145-160), Online publication date: 1-Jul-2002. Colhoun H, Schalkwijk C, Rubens M and Stehouwer C (2002) C-Reactive Protein in Type 1 Diabetes and Its Relationship to Coronary Artery Calcification, Diabetes Care, 10.2337/diacare.25.10.1813, 25:10, (1813-1817), Online publication date: 1-Oct-2002. Esposito K, Nicoletti G and Giugliano D (2014) Obesity, cytokines and endothelial dysfunction: A link for the raised cardiovascular risk associated with visceral obesity, Journal of Endocrinological Investigation, 10.1007/BF03345092, 25:7, (646-649), Online publication date: 1-Jul-2002. Tracy R (2003) Atherogenesis and Coronary Heart Disease International Textbook of Diabetes Mellitus, 10.1002/0470862092.d1001 Spasov T, Pop-Traykova L, Isoski D, Ivanova I and Dimitrov N (2019) MESENTERY – A NEW OR ALREADY KNOWN HUMAN ORGAN, Trakia Journal of Sciences, 10.15547/tjs.2019.s.02.022, 17:Suppl. 2, (100-102) Camelo L, Giatti L, Neves J, Lotufo P, Benseñor I, Chor D, Griep R, Fonseca M, Vidigal P, Kawachi I, Schmidt M, Barreto S and Shiels P (2014) Life Course Socioeconomic Position and C-Reactive Protein: Mediating Role of Health-Risk Behaviors and Metabolic Alterations. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil), PLoS ONE, 10.1371/journal.pone.0108426, 9:10, (e108426) June 2001Vol 21, Issue 6 Advertisement Article InformationMetrics https://doi.org/10.1161/01.ATV.21.6.881 Originally publishedJune 1, 2001 Keywordsobesityinflammationcardiovascular diseasePDF download Advertisement
Referência(s)